Interestingly, SF3B1 mutations correlate with good prognosis in MDS and UVM patients [28,29], while a reduced overall survival was observed in CLL and luminal B and progesterone receptor-negative breast cancer patients [30,31,32]. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.